← All trials
NCT03329950
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2017
- Primary completion
- Jul 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 145
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Celldex TherapeuticsLead sponsor
Drugs studied
Indications studied
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Hamartoma
- Head and Neck Neoplasms
- Liver Neoplasms
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Waldenstrom Macroglobulinemia
- Melanoma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Stomach Neoplasms
- Tissues
- Colorectal Neoplasms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Cholangiocarcinoma
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.